Fresenius stock gains as Barclays reiterates Buy rating and 57.50-euro target

Published on 09/16/2026 at 15:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock traded around 46.08 euros on Xetra on September 16, 2026 after Barclays reaffirmed its Buy rating with a 57.50-euro price target. The shares had closed at 45.39 euros on September 15, 2026, leaving about 24.8 percent upside to the target.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius SE & Co. KGaA stock (ISIN DE0005785604) traded at 46.08 euros on Xetra on September 16, 2026, up about 1.5 percent from the previous close of 45.39 euros and still roughly 24.8 percent below a reiterated analyst price target of 57.50 euros.

Barclays sticks to Buy rating and 57.50-euro target

According to finanzen.ch on September 16, 2026, Barclays Capital continues to rate Fresenius stock Overweight and maintains a price target of 57.50 euros, framing the shares as a Buy opportunity in its latest update.

As the same overview from MarketScreener reports on September 16, 2026, Barclays analyst Hassan Al-Wakeel keeps a positive stance on Fresenius and explicitly reiterates the Buy recommendation, while leaving the 57.50-euro price objective unchanged.

Per data cited by MarketScreener, Fresenius shares had last closed at 45.39 euros on September 15, 2026, so the Barclays target implies upside of about 12.11 euros or roughly 26.7 percent from that closing level, underlining the scope analysts still see for the stock.

Recent performance and valuation context

According to price data summarized by Bolsamania, Fresenius stock closed the Xetra session on September 15, 2026 at 45.39 euros, down 0.69 percent or 0.315 euros on the day, with a market capitalization of about 25,565.34 million euros.

On September 16, 2026, intraday data cited by finanzen.ch show Fresenius shares rising about 1.5 percent to 46.08 euros in the Xetra session, with roughly 258,991 shares changing hands, indicating solid trading interest around the analyst reaffirmation.

The analyst overview on MarketScreener notes an average consensus price target of 55.59 euros for Fresenius, which stands 22.46 percent above the latest closing price of 45.39 euros, suggesting that Barclays is slightly more optimistic than the consensus but broadly aligned with a positive analyst view.

Fundamentals and upcoming Q3 2026 results

In the same analyst context, MarketScreener highlights that Fresenius delivered second-quarter 2026 results ahead of estimates and raised certain targets for 2026, a combination that the analysis says has helped to reduce perceived risks around the company’s outlook.

Although the detailed revenue and earnings figures for Q2 2026 are not broken out in the brief snippets, the characterization of the quarter as beating estimates and supporting raised guidance places the current Barclays rating in a fundamental context where recent operational performance has positively surprised the market.

The same financial calendar on MarketScreener indicates that Fresenius is scheduled to publish its third-quarter 2026 results on November 4, 2026, giving investors a clear upcoming checkpoint at which the company’s execution on its updated targets will be reassessed.

Stock level and investor takeaway

As of the Xetra session on September 16, 2026, Fresenius stock traded at 46.08 euros, compared with the September 15, 2026 close of 45.39 euros and well below both the Barclays price target of 57.50 euros and the consensus target of 55.59 euros, leaving a double-digit percentage gap that investors will watch closely into the Q3 2026 earnings release.